Compare Stocks: TRDA, SVRA, FBRX, and WVE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$76.93 +0.1%	$45.68	$10.11 ▼ $77.20	$1.07B	2.6	643,616 shs	6.37 million shs
SVRA Savara	$5.57 +3.6%	$5.67	$2.92 ▼ $7.01	$1.15B	0.29	1.61 million shs	749,322 shs
TRDA Entrada Therapeutics	$7.77 +6.9%	$6.96	$5.02 ▼ $16.45	$300.91M	-0.26	329,013 shs	149,883 shs
WVE WAVE Life Sciences	$5.41 +2.3%	$5.86	$5.01 ▼ $21.73	$1.07B	-1.26	3.87 million shs	1.83 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	-0.01%	+0.01%	+57.35%	+278.53%	+545.51%
SVRA Savara	0.00%	-3.59%	-2.72%	+5.71%	+76.07%
TRDA Entrada Therapeutics	-0.68%	+3.27%	+5.52%	+20.36%	+31.70%
WVE WAVE Life Sciences	+3.93%	+4.75%	-9.11%	-14.54%	-45.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$76.93 +0.1%	$45.68	$10.11 ▼ $77.20	$1.07B	2.6	643,616 shs	6.37 million shs
SVRA Savara	$5.57 +3.6%	$5.67	$2.92 ▼ $7.01	$1.15B	0.29	1.61 million shs	749,322 shs
TRDA Entrada Therapeutics	$7.77 +6.9%	$6.96	$5.02 ▼ $16.45	$300.91M	-0.26	329,013 shs	149,883 shs
WVE WAVE Life Sciences	$5.41 +2.3%	$5.86	$5.01 ▼ $21.73	$1.07B	-1.26	3.87 million shs	1.83 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	-0.01%	+0.01%	+57.35%	+278.53%	+545.51%
SVRA Savara	0.00%	-3.59%	-2.72%	+5.71%	+76.07%
TRDA Entrada Therapeutics	-0.68%	+3.27%	+5.52%	+20.36%	+31.70%
WVE WAVE Life Sciences	+3.93%	+4.75%	-9.11%	-14.54%	-45.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.85% Downside
SVRA Savara	2.88	Moderate Buy	$10.14	85.60% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	133.71% Upside
WVE WAVE Life Sciences	2.94	Moderate Buy	$22.53	318.53% Upside

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, FBRX, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
TRDA Entrada Therapeutics	$4.69M	63.11	N/A	N/A	$8.01 per share	0.95
WVE WAVE Life Sciences	$42.73M	24.82	N/A	N/A	$3.10 per share	1.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	N/A
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	N/A
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	N/A

Latest TRDA, SVRA, FBRX, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	10.01	10.01
SVRA Savara	0.21	10.13	10.13
TRDA Entrada Therapeutics	N/A	10.89	10.89
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
SVRA Savara	87.93%
TRDA Entrada Therapeutics	86.39%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	4.40%
SVRA Savara	5.30%
TRDA Entrada Therapeutics	9.49%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
SVRA Savara	20	205.46 million	194.57 million	Optionable
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

TRDA, SVRA, FBRX, and WVE Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13, 2026 | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13, 2026 | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12, 2026 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11, 2026 | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

August 5, 2026 | theglobeandmail.com

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026 | globenewswire.com

Mizuho Lowers WAVE Life Sciences (NASDAQ:WVE) Price Target to $23.00

August 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Upcoming Investor Conferences

August 4, 2026 | globenewswire.com

HC Wainwright Issues Optimistic Outlook for WVE Earnings

August 4, 2026 | marketbeat.com

Wells Fargo Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

August 1, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, FBRX, and WVE Company Descriptions

Forte Biosciences NASDAQ:FBRX

$76.92 +0.05 (+0.06%)

As of 03:58 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Savara NASDAQ:SVRA

$5.56 +0.20 (+3.63%)

As of 03:58 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Entrada Therapeutics NASDAQ:TRDA

$7.77 +0.50 (+6.86%)

As of 03:58 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

WAVE Life Sciences NASDAQ:WVE

$5.41 +0.12 (+2.29%)

As of 03:58 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, FBRX, and WVE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, SVRA, FBRX, and WVE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, SVRA, FBRX, and WVE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, FBRX, and WVE Company Descriptions

Forte Biosciences NASDAQ:FBRX

Savara NASDAQ:SVRA

Entrada Therapeutics NASDAQ:TRDA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, FBRX, and WVE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, SVRA, FBRX, and WVE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, SVRA, FBRX, and WVE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, FBRX, and WVE Company Descriptions

Forte Biosciences NASDAQ:FBRX

Savara NASDAQ:SVRA

Entrada Therapeutics NASDAQ:TRDA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools